Among the plethora of options available for the management of T2DM, Insulin stands out as having maximum glucose-lowering efficacy. However, in clinical practise, glycemic control remains suboptimal despite the initiation of insulin therapy, possibly due to therapeutic or clinical inertia. As many as 30 - 50% of patients with
T2DM may remain above their glucose target 6 months after starting basal insulin.
Below is a case study about Suman, 51 year old female with type 2 Diabetes Mellitus since past 10 years.
- #endo-diabetology
Like
Answers
Save
Share